Month: June 2020

MCH Group Cancels Upcoming Art Basel Show in September 2020In view of the current global conditions, MCH Group has no option but to cancel the upcoming editions of Art Basel in Basel and Design Miami Basel, which had been postponed to mid-September 2020. The decision to cancel Art Basel was made after extensive consultation with many Art Basel gallerists, collectors, partners, as well as external experts. The primary considerations were the fundamental health and safety risks for everyone involved, the financial risks for exhibitors and partners, the ongoing impediments to international travel, and the fact that the regulatory environment around large-scale events in Switzerland has yet to be finalized.Marc Spiegler, Member of MCH Group’s Executive Board and Global Director Art Basel, explains: “We are aware that our galleries...

Hexagon Mobile Pipeline®, a Hexagon Composites subsidiary, has received a substantial contract for TITAN® 53 transport modules from Xpress Natural Gas LLC (XNG) a leading full-service provider of compressed natural gas (CNG). The strategic agreement has a total value of USD 7.3 million (approx. NOK 70.2 million) and includes additional purchase and rental options through 2021. The TITAN® 53 large-capacity Mobile Pipeline® modules will serve virtual interconnect projects providing natural gas to communities and industries that do not have access to sufficient pipeline capacity in the US.“Since XNG started operations in early 2013, Hexagon’s Titan products have proven to be high-quality products that deliver safety, reliability and performance,” says John Nahill, CEO and co-founder of Xpress Natural Gas. “The higher...

–Data strongly support expanding development into mast cell driven diseases––Data presented in a late-breaking session at EAACI Annual Congress 2020–HAMPTON, N.J., June 06, 2020 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced results from the Company’s Phase 1 randomized, double-blind, placebo-controlled, dose escalation study of KIT inhibitor CDX-0159 in healthy subjects. Data (presentation #1829) were featured in a late breaking presentation today at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020.CDX-0159 demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, consistent with systemic mast cell suppression. A single dose of CDX-0159 induced dose-dependent tryptase reduction below the level of...

RESEARCH TRIANGLE PARK, N.C., June 06, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented findings from two patient surveys conducted to gain insights into patients’ current hereditary angioedema (HAE) treatment expectations, experience and satisfaction. Patient-reported attack history shows patients treated with current injectable or infused prophylactic medications (Takhzyro®, Haegarda®, Cinryze®) continue to experience breakthrough attacks with a mean ranging from 0.9 to 1.8 attacks over the three months prior to survey.In addition, the majority of patients surveyed did not expect to have zero attacks even when taking prophylaxis therapy.The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress.“While the injectable and infused medications introduced...

RESEARCH TRIANGLE PARK, N.C., June 06, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from the APeX-2 and APeX-S clinical trials, which showed that hereditary angioedema (HAE) patients taking oral, once-daily berotralstat experienced sustained decreases in their attack frequency and improvements in quality of life (QoL) scores over 48 weeks. Berotralstat was also safe and generally well-tolerated over 48 weeks in both APeX-2 and APeX-S.The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress.“As HAE patients continue in our long‑term clinical trials, we are seeing reductions in attack rate and increases in QoL scores which highlight the impact oral, once-daily berotralstat could have in reducing the burden of disease for patients currently...

Результаты продолжающегося открытого дополнительного (OLE) исследования  краеугольного исследования NEURO–TTR, опубликованного в Европейском журнале неврологии, показывают, что у пациентов, принимавших TEGSEDI® (инотерсен), наблюдались устойчивое улучшение невропатического прогрессирования через 39 месяцев терапии и клинически соответствующие улучшения в показателях качества жизни по сравнению с естественным протеканием  болезни без вмешательства.Новых сигналов безопасности обнаружено не былo.TEGSEDI представляет собой домашнюю подкожную инъекцию.БОСТОН и КАРЛСБАД, Калифорния, June 06, 2020 (GLOBE NEWSWIRE) — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) и Akcea Therapeutics, Inc. (NASDAQ: AKCA), контрольный пакет акций которой пренадлежит Ionis Pharmaceuticals, Inc., сегодня анонсировали публикацию долгосрочных данных открытого...

SANTA MONICA, Calif., June 05, 2020 (GLOBE NEWSWIRE) — Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of the Defendants, Teva Pharmaceuticals Industries Ltd. Opiant’s commercial partner Emergent BioSolutions, intends to appeal the decision to the Court of Appeals for the Federal Circuit.“While we are disappointed by the decision today, we are mindful of the important role NARCAN® Nasal Spray plays across the United States in helping our communities save lives from opioid overdose,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. “With our pipeline and strong financial position, we remain committed to develop best-in-class medicines for addiction and overdose.”About Opiant...

VANCOUVER, British Columbia, June 05, 2020 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC” or the “Company”) has filed its financial results for the fourth quarter and fiscal year ended December 31, 2019. All figures are in CDN unless otherwise noted.2019 Financial Highlights:Loss from continuing operations for the year ended December 31, 2019 was $3.3M, a decrease of $1.1M year over year. Through the restructuring of its operations, the Company has reduced its working capital deficit by approximately $1.6M, from $5.12M to $3.5M, between the interim period ended September 30, 2019 and the year ended December 31, 2019. Gross margin of $0.08M at 54% margin in 2019 compared to $0.25M at 46% margin in 2018. Disposed of the UK operations reducing a continued drain on cash...

CALGARY, Alberta, June 05, 2020 (GLOBE NEWSWIRE) — Pulse Seismic Inc. (TSX:PSD) (OTCQX:PLSDF) (“Pulse” or the “Company”) is pleased to report its financial and operating results for the three months ended March 31, 2020. The audited consolidated financial statements, accompanying notes and MD&A are being filed on SEDAR (www.sedar.com) and will be available on Pulse’s website at www.pulseseismic.com.HIGHLIGHTS FOR THE THREE MONTHS ENDED MARCH 31, 2020Data library sales were $2.2 million for the three months ended March 31, 2020 compared to $5.3 million for the three months ended March 31, 2019;The net loss was $2.8 million or $0.05 per share compared to a net loss of $2.7 million or $0.05 per share in the first quarter of 2019;Cash EBITDA was $1.1 million or $0.02 per share compared to $3.1 million or $0.06 per share for the...

GAITHERSBURG, Md., June 05, 2020 (GLOBE NEWSWIRE) — Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of the Defendants, Teva Pharmaceuticals Industries Ltd. Emergent intends to appeal the decision to the Court of Appeals for the Federal Circuit.“We are understandably disappointed by the decision today,” said Doug White, senior vice president and devices business unit head at Emergent BioSolutions. “We remain committed to expanding awareness, maintaining affordability, and increasing access to NARCAN® Nasal Spray, to improving public health, and to assisting those dedicated to ending the opioid crisis.”Financial ConsiderationsThe company will provide an update to its 2020 financial outlook...